about
Evaluation of a Mixing versus a Cycling Strategy of Antibiotic Use in Critically-Ill Medical Patients: Impact on Acquisition of Resistant Microorganisms and Clinical OutcomesHIV Incidence and Spatial Clustering in a Rural Area of Southern MozambiqueHIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco.Malaria epidemiology in Lihir Island, Papua New Guinea.Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial.Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study.Do Size and Insecticide Treatment Matter? Evaluation of Different Nets against Phlebotomus argentipes, the Vector of Visceral Leishmaniasis in Nepal.Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis.Evaluation of a new, rapid, simple test for the detection of influenza virus.Evaluation of inflammatory and renal-injury markers in women treated with antibiotics for acute pyelonephritis caused by Escherichia coli.Staphylococcus lugdunensis infective endocarditis: description of 10 cases and analysis of native valve, prosthetic valve, and pacemaker lead endocarditis clinical profilesAltered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response.Health care-associated native valve endocarditis: importance of non-nosocomial acquisition.Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial.Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population.Tolerability of integrase inhibitors in a real-life setting.Sensitivity and specificity of a rapid point-of-care test for active yaws: a comparative study.Proinflammatory responses and higher IL-10 production by T cells correlate with protection against malaria during pregnancy and delivery outcomes.Psychosocial adjustment to orthotopic liver transplantation in 266 recipients.Pilot study assessing HIV vaccine trial readiness among female sex workers, injection and non-injection drug users, and men who have sex with men in Spain.Neurological involvement in patients with acute/recent HIV-1 infection. A case-control study.Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components.Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1-infected patients.Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The AdThe model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.Erratum: Evaluation of a new, rapid, simple test for the detection of influenza virus.Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.Improvement of psychosocial adjustment to HIV-1 infection through a cognitive-behavioral oriented group psychotherapy program: a pilot study.Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study.Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality.
P50
Q28550780-DDD11F5A-5C56-4362-AB09-0E67B4E2D2E8Q28647478-14D8CF8A-665E-4882-9FCE-1ADFB0CC554BQ30226766-353D102B-159F-4B6D-8299-BF3E3B25CBA1Q30394036-B349D89F-B05E-4606-B52E-23FF5667D70AQ34030229-780F4CE9-D9E5-453C-A0FA-824D5E22DFB3Q34030229-7DDEB103-B138-40AD-BADB-65681A460F66Q34548243-71275955-BAFC-4F96-933F-1E5CFE467E62Q34663827-DFD9B01F-A6B9-47E7-8633-79B684BA8B72Q34672844-79D08DAD-432C-4494-B103-B73F105BB8F6Q35095569-3C557FA9-95FC-4745-9601-6BCDF6997AF6Q35205172-5C0BF522-977A-4E71-A756-7948DD89E6F6Q35542067-6DBC59A2-1D95-4669-B2BD-CC81578F8A38Q35583667-C6B76700-7C9F-49E7-852A-C9A3FAE27869Q35883877-6469C917-1AE3-4C2C-8D80-F6895C68E57EQ36763637-1C2AAE92-82B8-461C-9B5C-70CE7B99085FQ38383280-A7132369-3EBE-4E1A-BDC5-BEA600AC24EDQ38462726-448C8B85-6906-441D-BB43-1AB4080C1E33Q38605447-4E5988A6-1D73-4C31-A9D8-D9CA4EDDB6E2Q38883840-FB7DF0DE-689D-46A3-832B-AACFC6E0776DQ38885484-9E15BFE3-1B79-4EAB-82AA-45BBC9FA359FQ39034583-78258E50-39B3-488C-A7E1-54EA313786D8Q39675519-8D4BFEA1-A9E8-42ED-BBF0-D8148EE873D5Q40024554-E8FED73B-92DB-4882-BCB0-2F9FF0CBE496Q40118949-2E3E753B-93A5-4F31-B1B4-47CF7570B4C0Q40463331-EF0213F8-4448-4710-B482-5DE75D46EA08Q40551862-23D2A40B-3032-4E8E-941A-C18634FF4453Q42930897-44D3C3D9-AB49-4551-AF4B-A66EEA069491Q42972719-BE8C4AD1-C9A4-4C92-BFA0-9A3111BF752AQ42990523-8F49FFA4-52D1-4035-AA02-02DAEF075582Q43033610-C5FF6910-39B2-4714-9EAE-8148321DB187Q43242359-852CBF91-D8D9-4452-9773-2E08764873AFQ43408598-195E6E75-A163-4911-8B86-BC7A96EDC195Q44226223-3130CD81-CBEF-4FB8-A566-69F60AA5188AQ44340780-3E491292-2366-467B-9B14-357BB070B230Q44408446-03F0B36F-AEF0-4B66-9264-A48107FD01CDQ44580891-DEE439C6-A49F-4050-9B75-2EBBA4E7B5BDQ44669983-96CE29EB-2F14-4B60-819C-C6E293EC5969Q44807945-C54520AC-C190-434C-B502-3EA43E03A158Q44820800-C038E847-2C68-4837-8851-FEA5323B673BQ44964458-5A6928EB-39F3-4237-B980-57A2CE46FEE8
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Elisa De Lazzari
@ast
Elisa De Lazzari
@en
Elisa De Lazzari
@es
Elisa De Lazzari
@nl
Elisa De Lazzari
@sl
type
label
Elisa De Lazzari
@ast
Elisa De Lazzari
@en
Elisa De Lazzari
@es
Elisa De Lazzari
@nl
Elisa De Lazzari
@sl
prefLabel
Elisa De Lazzari
@ast
Elisa De Lazzari
@en
Elisa De Lazzari
@es
Elisa De Lazzari
@nl
Elisa De Lazzari
@sl
P106
P21
P31
P496
0000-0003-2614-6545